Latest European Expansion News

Collins Foods Limited has reported record half-year revenues of $750.3 million, with underlying net profit after tax surging 29.5%. The company’s operational improvements and expansion in Europe underpin an upgraded FY26 outlook.

South Harz Potash Limited (SHP) has secured an option to acquire the Glava copper-gold project in Sweden, complementing its advanced potash development in Germany and reinforcing its multi-commodity European strategy.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

Sprintex Limited has transitioned from development to commercial execution, securing major contracts in Europe, China, and India while raising A$1.5m to fund expansion.

AML3D Limited reported steady quarterly receipts alongside a landmark US Navy Letter of Intent and significant orders, underpinning a major growth phase in the US and Europe.

Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.